PMID- 31842811 OWN - NLM STAT- MEDLINE DCOM- 20200506 LR - 20221207 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 19 IP - 1 DP - 2019 Dec 16 TI - Vaginal dose of radical radiotherapy for cervical cancer in China: a multicenter study. PG - 1219 LID - 10.1186/s12885-019-6423-5 [doi] LID - 1219 AB - BACKGROUND: The posterior-inferior border of symphysis (PIBS) point system is a novel vaginal dose-reporting method and is a simple and reliable method proposed by the Medical University of Vienna proposed for both external-beam radiotherapy (EBRT) and brachytherapy (BT). In this multicenter study, we sought to first evaluate the vaginal radiation dose in Chinese cervical cancer patients according to the PIBS point system and then to analyze the factors influencing the dose distribution. METHODS: We collected data from the medical records of 936 cervical cancer patients who underwent concurrent radiochemotherapy at 13 different institutions in China. Radiation doses at points A, PIBS+ 2 cm, PIBS and PIBS-2 cm, International Commission on Radiation Units (ICRU)-R and ICRU-B were measured. RESULTS: The median total doses in EQD2(alpha/beta = 3) at points PIBS+ 2 cm, PIBS and PIBS-2 cm were 82.5 (52.7-392.1) Gy, 56.2 (51.4-82.1) Gy and 2.6 (0.9-7.4) Gy, respectively. The median total doses in EQD2(alpha/beta = 3) at ICRU-R and ICRU-B were 77.5 (54.8-132.4) Gy and 79.9 (60.7-133.7) Gy, respectively. The mean vaginal reference length (VRL) was 4.6 +/- 1.0 cm (median, 4.5 cm). In patients with VRL 4.5 cm, the mean total doses at these three points were 68.9, 0.5 and 54.5 Gy, respectively. Classification of patients revealed significant differences (P < 0.05) between these two groups. CONCLUSIONS: With the PIBS point system, Chinese patients with a shorter VRL of < 4.5 cm received higher radiation doses at the PIBS+ 2 cm, PIBS and PIBS-2 cm points than European and American patients. Further studies are required to establish the dose-effect relationships with these points as references. The study was registered as a clinical trial (NCT03257475) on August 22, 2017. FAU - Wang, Juan AU - Wang J AD - Department of Radiation Oncology, The First Affiliated Hospital of Xi'an Jiao Tong University, 277# West Yanta Road, Xi'an, Shaanxi, China. FAU - Zhang, Kai-Shuo AU - Zhang KS AD - Department of Radiation Oncology, The First Affiliated Hospital of Xi'an Jiao Tong University, 277# West Yanta Road, Xi'an, Shaanxi, China. FAU - Wang, Tao AU - Wang T AD - Department of Radiation Oncology, The First Affiliated Hospital of Xi'an Jiao Tong University, 277# West Yanta Road, Xi'an, Shaanxi, China. FAU - Liu, Zi AU - Liu Z AUID- ORCID: 0000-0001-6147-8444 AD - Department of Radiation Oncology, The First Affiliated Hospital of Xi'an Jiao Tong University, 277# West Yanta Road, Xi'an, Shaanxi, China. liuzmail@163.com. FAU - Wang, Rui-Hua AU - Wang RH AD - Department of Radiation Oncology, The First Affiliated Hospital of Xi'an Jiao Tong University, 277# West Yanta Road, Xi'an, Shaanxi, China. FAU - Zhang, Fu-Quan AU - Zhang FQ AD - Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100032, China. FAU - Yu, Lang AU - Yu L AD - Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100032, China. FAU - Ran, Li AU - Ran L AD - Department of Oncology, The Affiliated Hospital of Guizhou Medical Universty/Guizhou Cancer Hospital, Gui Yang, 550000, China. FAU - He, Jian-Li AU - He JL AD - Department of Radiation Oncology, General Hospital of Ningxia Medical University, Yin chuan, 750004, China. FAU - Wang, Ya-Li AU - Wang YL AD - Department of Radiation Oncology, The Second Affiliated hospital of Xi'an Jiao Tong University, Xi'an, 710004, China. FAU - Wei, Li-Chun AU - Wei LC AD - Department of Radiation Oncology, First Affiliated Hospital of Air Force Medical University, Xi'an, 710032, China. FAU - Shi, Mei AU - Shi M AD - Department of Radiation Oncology, First Affiliated Hospital of Air Force Medical University, Xi'an, 710032, China. FAU - Wang, Guo-Qing AU - Wang GQ AD - Department of Gynecology Oncology, Shaanxi Provincial Tumor Hospital, Xi'an, 710061, China. FAU - Wu, Chao-Qun AU - Wu CQ AD - Department of Radiation Oncology, The first people's Hospital of Kashi District, Xinjiang, 844000, China. FAU - Kang, Qi-Jun AU - Kang QJ AD - Department of Radiation Oncology, The first people's Hospital of Kashi District, Xinjiang, 844000, China. FAU - Yang, Jie AU - Yang J AD - Department of Radiation Oncology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumchi, 830002, China. FAU - Li, Sha AU - Li S AD - Department of Radiation Oncology, The 940th Hospital of Joint Logistics Support force of Chinese People's Liberation Army, Lan Zhou, 730050, China. FAU - Yang, Fei-Yue AU - Yang FY AD - Department of Oncology, Guizhou Provincial People's Hospital, Guiyang, 550002, China. FAU - Liu, Bao-Gang AU - Liu BG AD - Department of Radiation Oncology, The Second Affiliated Hospital of Shaanxi University of Chinese Medicine, Xian yang, 712046, China. FAU - Liu, Juan-Yue AU - Liu JY AD - Department of Radiation Oncology, Xi'an Gao Xin Hospital, Xi'an, 710000, China. FAU - Shi, Fan AU - Shi F AD - Department of Radiation Oncology, The First Affiliated Hospital of Xi'an Jiao Tong University, 277# West Yanta Road, Xi'an, Shaanxi, China. FAU - Su, Jin AU - Su J AD - Department of Radiation Oncology, The First Affiliated Hospital of Xi'an Jiao Tong University, 277# West Yanta Road, Xi'an, Shaanxi, China. FAU - Yuan, Wei AU - Yuan W AD - Department of Radiation Oncology, The First Affiliated Hospital of Xi'an Jiao Tong University, 277# West Yanta Road, Xi'an, Shaanxi, China. FAU - Drokow, Emmanuel Kwateng AU - Drokow EK AD - Department of Radiation Oncology, The First Affiliated Hospital of Xi'an Jiao Tong University, 277# West Yanta Road, Xi'an, Shaanxi, China. LA - eng SI - ClinicalTrials.gov/NCT03257475 GR - #81602676/the National Science Foundation of China/ PT - Clinical Trial PT - Journal Article PT - Multicenter Study DEP - 20191216 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 SB - IM MH - Adenocarcinoma/therapy MH - Adult MH - Asian People MH - *Brachytherapy MH - Carcinoma, Squamous Cell/therapy MH - *Chemoradiotherapy MH - China MH - Female MH - Humans MH - Middle Aged MH - Radiotherapy Dosage MH - Uterine Cervical Neoplasms/*therapy PMC - PMC6915922 OTO - NOTNLM OT - Cervical cancer OT - PIBS OT - Radiotherapy OT - Vaginal dose COIS- The authors declare that they have no competing interests. EDAT- 2019/12/18 06:00 MHDA- 2020/05/07 06:00 PMCR- 2019/12/16 CRDT- 2019/12/18 06:00 PHST- 2019/05/21 00:00 [received] PHST- 2019/12/03 00:00 [accepted] PHST- 2019/12/18 06:00 [entrez] PHST- 2019/12/18 06:00 [pubmed] PHST- 2020/05/07 06:00 [medline] PHST- 2019/12/16 00:00 [pmc-release] AID - 10.1186/s12885-019-6423-5 [pii] AID - 6423 [pii] AID - 10.1186/s12885-019-6423-5 [doi] PST - epublish SO - BMC Cancer. 2019 Dec 16;19(1):1219. doi: 10.1186/s12885-019-6423-5.